Here’s a surprising revelation: a new diagnosis of interstitial lung disease (ILD) doesn’t necessarily doom patients in the ICU. This finding challenges the common assumption that newly diagnosed ILD patients face worse outcomes when battling severe respiratory failure. But here’s where it gets even more intriguing—research shows their survival rates in intensive care units (ICUs) are nearly identical to those with long-standing ILD. Let’s dive into the details.
In a meticulous retrospective study, researchers analyzed 80 patients with ILD admitted to an adult ICU between 2009 and 2023, all grappling with severe acute respiratory failure. The patients were divided into two groups: those with new-onset ILD (symptoms appearing less than six months before admission) and those with established ILD (longer-standing symptoms). Shockingly, the overall ICU mortality rate was 50%, with no significant difference between the two groups—48% for new-onset ILD versus 51% for established ILD. And this is the part most people miss: despite new-onset cases spending more time in the ICU and on mechanical ventilation, these differences weren’t statistically significant.
But here’s where it gets controversial: While ICU mortality rates were similar, one-year survival rates told a slightly different story. Patients with new-onset ILD had a numerically higher one-year survival rate (51%) compared to those with established ILD (36%). Does this mean newly diagnosed patients have a hidden advantage? Or is it just a statistical blip? The debate is wide open.
Digging deeper, the study revealed that non-survivors were generally older, had higher severity scores (APACHE and SOFA), and were more likely to require invasive mechanical ventilation. Across the board, 64 patients needed mechanical ventilation, 23 received extracorporeal membrane oxygenation (ECMO), and 30 were on multiple immunosuppressive medications—highlighting the intense organ support required in these cases.
So, what does this mean for ICU decision-making? The findings suggest that a new ILD diagnosis shouldn’t automatically disqualify a patient from ICU admission. Instead, factors like age, physiological reserve, and severity scores should guide decisions. For pulmonologists, rheumatologists, and intensivists, this underscores the need for multidisciplinary collaboration and early referral to advanced care teams. But it also raises a critical question: Are we setting realistic goals of care for these high-risk patients?
This study, led by Soo I et al. and published in Thorax (2025), invites us to rethink our approach to ILD in the ICU. What’s your take? Do you agree that a new ILD diagnosis shouldn’t be a barrier to ICU admission, or are there nuances we’re missing? Share your thoughts in the comments—let’s spark a conversation!
